Boehringer Ingelheim receives Scottish approval for two therapies

Boehringer Ingelheim has announced that two of its medicines have been approved for use by NHS Scotland following a review by the Scottish Medicines Consortium (SMC).

The anticoagulant Pradaxa has been approved for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) by the regulator, as well as for the prevention of recurrent DVT and PE in adults.

Meanwhile, the drug Jardiance has also received the green light for restricted use in treating type 2 diabetes to improve glycaemic control in adults as an add-on combination therapy.

The approvals came after analysis by the SMC deemed that both products could be considered clinically effective and represent value for money.

Zinta Krumins, managing director of Boehringer Ingelheim in the UK and Ireland, said: "Living with the consequences of DVT/PE and diabetes can be devastating for people and we are proud to see our medicines able to help those suffering with these illnesses."

This comes after the firm's new lung cancer therapy nintedanib was recommended for EU approval by the European Medicines Agency's Committee for Medicinal Products for Human Use towards the end of last month.